These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34478233)

  • 1. Clinical outcomes according to lesion complexity in high bleeding risk patients treated with 1-month dual antiplatelet therapy following PCI: Analysis from the Onyx ONE clear study.
    Kandzari DE; Kirtane AJ; Mehran R; Price MJ; Simon DI; Latib A; Kedhi E; Abizaid A; Worthley SG; Zaman A; Hudec M; Stoler R; Choi JW; Kanitkar M; Conradie A; Tam CF; Walton A; Gruberg L; Ando K; Lee LC; Lung TH; Windecker S; Stone GW
    Catheter Cardiovasc Interv; 2022 Feb; 99(3):583-592. PubMed ID: 34478233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year results from Onyx ONE clear in patients with high bleeding risk on one-month DAPT with and without intracoronary imaging.
    Toth GG; Kandzari DE; Kirtane AJ; Windecker S; Latib A; Kedhi E; Mehran R; Price MJ; Choi JW; Caputo R; Troquay R; Diderholm E; Singh S; Brar SS; Loussararian A; Chetcuti S; Tulli M; Stone GW; Lung TH; Mylotte D
    Cardiovasc Revasc Med; 2024 Jan; 58():60-67. PubMed ID: 37550123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients.
    Kandzari DE; Kirtane AJ; Windecker S; Latib A; Kedhi E; Mehran R; Price MJ; Abizaid A; Simon DI; Worthley SG; Zaman A; Choi JW; Caputo R; Kanitkar M; McLaurin B; Potluri S; Smith T; Spriggs D; Tolleson T; Nazif T; Parke M; Lee LC; Lung TH; Stone GW;
    Circ Cardiovasc Interv; 2020 Nov; 13(11):e009565. PubMed ID: 33167705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients: Final 2-Year Results From Onyx ONE.
    Windecker S; Latib A; Kedhi E; Kirtane AJ; Kandzari DE; Mehran R; Price MJ; Abizaid A; Simon DI; Worthley SG; Zaman A; Hudec M; Poliacikova P; Kahar Bin Abdul Ghapar A; Selvaraj K; Petrov I; Mylotte D; Pinar E; Moreno R; Fabbiocchi F; Pasupati S; Kim HS; Aminian A; Tie C; Wlodarczak A; Hur SH; Marx SO; Ali ZA; Parke M; Lung TH; Stone GW;
    JACC Cardiovasc Interv; 2022 Jun; 15(11):1153-1163. PubMed ID: 35680195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial.
    Yamamoto K; Watanabe H; Morimoto T; Domei T; Ohya M; Ogita M; Takagi K; Suzuki H; Nikaido A; Ishii M; Fujii S; Natsuaki M; Yasuda S; Kaneko T; Tamura T; Tamura T; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Igarashi Hanaoka K; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    Circ Cardiovasc Interv; 2021 May; 14(5):e010384. PubMed ID: 34003662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and Rationale of the BIOFLOW-DAPT Trial: a Prospective, Randomized, Multicenter Study to Assess the Safety of the Orsiro Mission Stent Compared to the Resolute Onyx Stent in Subjects at High Risk for Bleeding in Combination with 1-Month Dual Antiplatelet Therapy.
    Landi A; Wlodarczak A; Tölg R; Kelbæk H; Legutko J; Galli S; Godin M; Toth GG; Lhermusier T; Honton B; Dietrich PL; Stammen F; Ferdinande B; Silvain J; Capodanno D; Cayla G; Valgimigli M;
    J Cardiovasc Transl Res; 2023 Oct; 16(5):1135-1143. PubMed ID: 37264295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Yeh RW; Kereiakes DJ; Steg PG; Cutlip DE; Croce KJ; Massaro JM; Mauri L;
    J Am Coll Cardiol; 2017 Oct; 70(18):2213-2223. PubMed ID: 29073947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting.
    Costa F; Van Klaveren D; Feres F; James S; Räber L; Pilgrim T; Hong MK; Kim HS; Colombo A; Steg PG; Bhatt DL; Stone GW; Windecker S; Steyerberg EW; Valgimigli M;
    J Am Coll Cardiol; 2019 Feb; 73(7):741-754. PubMed ID: 30784667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world reasons and outcomes for 1-month versus longer dual antiplatelet therapy strategies with a polymer-free BIOLIMUS A9-coated stent.
    Gallone G; D'Ascenzo F; Boccuzzi G; Cortese B; Di Biasi M; Omedè P; Capodanno D; Cerrato E; Vicinelli P; Infantino V; Poli A; Ugo F; Conrotto F; Grigis G; Varbella F; Latini RA; D'Urbano M; Montabone A; Senatore G; Ferrara E; D'Amico M; De Ferrari GM; Ielasi A
    Catheter Cardiovasc Interv; 2020 Sep; 96(3):E248-E256. PubMed ID: 32012453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous Coronary Intervention Complexity and Risk of Adverse Events in relation to High Bleeding Risk among Patients Receiving Drug-Eluting Stents: Insights from a Large Single-Center Cohort Study.
    Wang HY; Wang Y; Yin D; Gao RL; Yang YJ; Xu B; Dou KF
    J Interv Cardiol; 2020; 2020():2985435. PubMed ID: 32405273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI.
    Wang HY; Dou KF; Yin D; Zhang D; Gao RL; Yang YJ
    BMC Cardiovasc Disord; 2020 Jul; 20(1):313. PubMed ID: 32611318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
    Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
    JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
    Valgimigli M; Cao D; Angiolillo DJ; Bangalore S; Bhatt DL; Ge J; Hermiller J; Makkar RR; Neumann FJ; Saito S; Picon H; Toelg R; Maksoud A; Chehab BM; Choi JW; Campo G; De la Torre Hernandez JM; Kunadian V; Sardella G; Thiele H; Varenne O; Vranckx P; Windecker S; Zhou Y; Krucoff MW; Ruster K; Zheng Y; Mehran R;
    J Am Coll Cardiol; 2021 Nov; 78(21):2060-2072. PubMed ID: 34794687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymer-Free Biolimus-Eluting Stents or Polymer-Based Zotarolimus-Eluting Stents for Coronary Bifurcation Lesions.
    Gallone G; D'Ascenzo F; Ielasi A; Landra F; Stefanini GG; Di Biasi M; Mancone M; Tomai F; Infantino V; Rognoni A; Briguori C; Boccuzzi G; Smolka G; Chiarito M; Capodanno D; Chieffo A; Fabbiocchi F; Poli A; Tespili M; D'Urbano M; Giordano A; Escaned J; De Ferrari GM; Sardella G
    Cardiovasc Revasc Med; 2022 Feb; 35():66-73. PubMed ID: 33903036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clopidogrel Monotherapy After 1-Month DAPT in Patients With High Bleeding Risk or Complex PCI.
    Yamamoto K; Watanabe H; Morimoto T; Obayashi Y; Natsuaki M; Domei T; Yamaji K; Suwa S; Isawa T; Watanabe H; Yoshida R; Sakamoto H; Akao M; Hata Y; Morishima I; Tokuyama H; Yagi M; Suzuki H; Wakabayashi K; Suematsu N; Inada T; Tamura T; Okayama H; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Morino Y; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    JACC Asia; 2023 Feb; 3(1):31-46. PubMed ID: 36873770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit of Prolonged Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stent for Coronary Bifurcation Lesions: Results From the Coronary Bifurcation Stenting Registry II.
    Jang WJ; Ahn SG; Song YB; Choi SH; Chun WJ; Oh JH; Cho SW; Kim BS; Yoon JH; Koo BK; Yu CW; Jang YS; Tahk SJ; Kim HS; Gwon HC; Lee SY; Hahn JY
    Circ Cardiovasc Interv; 2018 Jul; 11(7):e005849. PubMed ID: 30006330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
    Valgimigli M; Patialiakas A; Thury A; McFadden E; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Airoldi F; Ferlini M; Liistro F; Dellavalle A; Vranckx P; Briguori C;
    J Am Coll Cardiol; 2015 Mar; 65(8):805-815. PubMed ID: 25720624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation.
    Généreux P; Giustino G; Redfors B; Palmerini T; Witzenbichler B; Weisz G; Stuckey TD; Maehara A; Mehran R; Kirtane AJ; Stone GW
    Int J Cardiol; 2018 Oct; 268():61-67. PubMed ID: 30041804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
    Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Antiplatelet Therapy Duration Determines Outcome After 2- But Not 1-Stent Strategy in Left Main Bifurcation Percutaneous Coronary Intervention.
    Rhee TM; Park KW; Kim CH; Kang J; Han JK; Yang HM; Kang HJ; Koo BK; Kim HS
    JACC Cardiovasc Interv; 2018 Dec; 11(24):2453-2463. PubMed ID: 30573055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.